Business Context and Reporting Period
Company: Establishment Labs Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 26, 2022
Event: Entry into a Material Definitive Agreement (Credit Agreement and Guaranty).
Key Financial Metrics and Debt Structure
This filing details a new credit facility rather than reporting operational financial results (revenue, profit, or cash flow) for a specific period.
- Total Facility Size: Up to $225,000,000 in Term Loans.
- Initial Funding (Tranche A): $150,000,000 advanced on the Closing Date.
- Future Tranches:
- Tranche B: $25,000,000 (Available by Sept 30, 2023, subject to gross sales thresholds).
- Tranche C: $25,000,000 (Available by March 31, 2024, subject to FDA approvals or gross sales thresholds).
- Tranche D: $25,000,000 (Available by Dec 31, 2024, subject to both FDA approvals and gross sales thresholds).
- Interest Rate: 9% per annum (reduces to 8.25% after Tranche D Funding Milestone).
- Original Issue Discount (OID): 2% of principal per tranche.
- Exit Fee: 3% of principal amount upon payment or prepayment.
- Maturity Date: 5-year anniversary of the Closing Date (April 26, 2027).
- Collateral: Security interest in substantially all personal property, rights, and assets of the Company and guarantor subsidiaries.
Material Changes and Use of Proceeds
The Company refinanced existing indebtedness under a 2017 Credit Agreement. Proceeds from the new Term Loans are designated for:
- Refinancing existing indebtedness.
- Funding commercialization of product offerings outside the United States.
- Construction of a third manufacturing facility in Costa Rica.
- Ongoing U.S. regulatory filings related to Motiva Implants.
- Working capital and general corporate purposes, including transaction fees.
Guidance, Covenants, and Risks
Financial Covenants:
- Liquidity: Must maintain minimum liquidity of $20,000,000 (increasing to $25,000,000 after Tranche B funding).
- Gross Sales: Until 12-consecutive month gross sales reach $200,000,000, the Company must meet minimum gross sales targets exceeding 50% of specified quarterly targets. An equity cure right is available for failures to meet this covenant.
Restrictive Covenants: Limitations on incurring additional indebtedness, consummating mergers/acquisitions, and creating non-permitted liens without consent.
Prepayment Penalties: Significant yield protection premiums apply to prepayments before the 2nd anniversary (sum of accrued interest through 2nd anniversary + 4% of principal). Premiums decrease to 4%, 2%, and 0% in subsequent years.
Interest Payment Flexibility: Prior to the 2nd anniversary, the Company may pay 600 basis points of the interest rate in kind (PIK).
Investor Verification Checklist
- Verify the Company's current cash position to ensure compliance with the $20,000,000 minimum liquidity covenant.
- Monitor gross sales performance against the 50% target threshold required to avoid covenant breaches.
- Track progress on FDA approvals for Motiva Implants, which is a condition for Tranche C and D funding.
- Review the impact of the 2% OID and 3% Exit Fee on the effective cost of capital.
- Assess the risk of prepayment penalties if the Company seeks to refinance or repay debt before the 2nd anniversary.